EU medtech reform proposals 'don't go far enough'
This article was originally published in SRA
Executive Summary
The European Commission’s recently published plans to strengthen the current regulatory framework for medical devices do not go far enough, a group of four European organisations representing among other things health professionals, health insurance bodies and social security systems and patients groups is arguing1. The proposals are not sufficient to safeguard patients from potentially harmful devices, they say, and they call for a centralised pre-market approval system where safety, efficacy and a positive risk-benefit balance must be proven through high-quality clinical investigations.
You may also be interested in...
EU Regulatory Roundup, March 2024: Busy Agenda In Broad Range Of Key Areas
March was an important month for EU medtech regulation with an interesting spread of news relating to the Medical Device and IVD Regulations, the Batteries Regulation, the Artificial Intelligence Act and more.
EU’s Revised Phthalates Guideline Features New Annexes Focused On Alternatives
The effects of phthalates, plasticizers used in many medical devices, on the human endocrine system, have long been debated. But how safe are the alternatives? Updated guidelines give more insight.
Non-Medical Brain Stimulation Devices: Could They Be Down-Classified Again In the EU?
Six types of products that do not have an intended medical purpose fall under the scope of the Medical Device Regulation. Understanding their risks is complex and subject to regular re-examination by the European Commission.